BiotechTube
Inventprise

Inventprise

Redmond, United States· Est.
inventprise.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Founded in 2014 (originating from 2012), Inventprise is a private, clinical-stage biotech based in Redmond, Washington, developing novel conjugate vaccines using its proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker platform. Its lead candidate is a 25-valent pediatric pneumococcal conjugate vaccine (IVT PCV-25), and its pipeline includes Phase 1/2 candidates for Group B Streptococcus (GBS), Shigella, Klebsiella, and COVID-19. Led by vaccine industry veteran Dr. Subhash Kapre, the company has built state-of-the-art manufacturing capacity and grown to over 200 employees, positioning itself to address significant global infectious disease burdens.

Infectious Diseases

Technology Platform

Proprietary Hydrazide-PEG-Hydrazide (Hz-PEG-Hz) linker conjugation platform for creating specific, highly immunogenic, and broad-spectrum conjugate vaccines.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

Significant unmet need for broader-spectrum pneumococcal vaccines and first-ever vaccines for pathogens like Group B Streptococcus and Shigella.
Proprietary conjugation platform and in-house manufacturing could enable cost-effective, scalable production for global markets, including partnerships with global health organizations.

Risk Factors

High clinical development risk; candidates may fail in later-stage trials.
Intense competition in the pneumococcal market from large, established pharmaceutical companies with significant commercial resources.
Dependence on raising substantial additional capital as a private, pre-revenue company to fund expensive Phase 3 trials and operations.

Competitive Landscape

The pneumococcal vaccine market is dominated by Pfizer (Prevnar family) and Merck, creating high barriers to entry. For GBS and Shigella, the competitive landscape is less crowded but includes other biotechs and pharma companies in development. Inventprise's differentiation hinges on its proprietary platform's potential for superior immunogenicity and breadth.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →